The EMBO Journal3 小时
LATS1/2 inactivation in the mammary epithelium drives the evolution of a tumor-associated niche
LATS1/2-inactivation and consequent nuclear YAP/TAZ hyperactivation in the mammary epithelium drives the development of a pro ...
Chardan Capital Cuts 4D Molecular Therapeutics (NASDAQ:FDMT) Price Target to $30.00
D Molecular Therapeutics (NASDAQ:FDMT – Free Report) had its price target decreased by Chardan Capital from $39.00 to $30.00 in a report released on Tuesday,Benzinga reports. Chardan Capital currently ...